These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12170448)

  • 1. Docetaxel in ovarian cancer: phase III perspectives and future development.
    Kaye SB; Vasey PA
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):22-7. PubMed ID: 12170448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Docetaxel and ovarian cancer].
    Ray-Coquard I
    Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the treatment of ovarian cancer. Scottish Gynaecological Cancer Trials Group.
    Kaye SB
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S29-32. PubMed ID: 10630366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integration of docetaxel into first-line chemotherapy for ovarian cancer.
    Kaye SB;
    Int J Gynecol Cancer; 2001; 11 Suppl 1():31-3. PubMed ID: 11489000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.
    Belani CP;
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel in the treatment of ovarian cancer.
    Kavanagh JJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel: an alternative taxane in ovarian cancer.
    Katsumata N
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
    Vasey PA
    J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer.
    Aoki Y; Sato T; Tsuneki I; Watanabe M; Kase H; Fujita K; Kurata H; Tanaka K
    Int J Gynecol Cancer; 2002; 12(6):704-9. PubMed ID: 12445246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
    Georgoulias V
    Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
    Vasey PA; Atkinson R; Coleman R; Crawford M; Cruickshank M; Eggleton P; Fleming D; Graham J; Parkin D; Paul J; Reed NS; Kaye SB
    Br J Cancer; 2001 Jan; 84(2):170-8. PubMed ID: 11161372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
    Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
    Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.